The impact of Aprepitant on Nausea and Vomiting following Laparoscopic Sleeve Gastrectomy: A Blinded Randomized Controlled Trial.
Aprepitant
Bariatric anesthesia
Bariatric surgery
Laparoscopic sleeve gastrectomy
Obesity
Ponv
Postoperative nausea and vomit
Journal
Obesity surgery
ISSN: 1708-0428
Titre abrégé: Obes Surg
Pays: United States
ID NLM: 9106714
Informations de publication
Date de publication:
02 Mar 2024
02 Mar 2024
Historique:
received:
07
12
2023
accepted:
22
02
2024
revised:
19
02
2024
medline:
2
3
2024
pubmed:
2
3
2024
entrez:
1
3
2024
Statut:
aheadofprint
Résumé
Laparoscopic sleeve gastrectomy (LSG) is associated with postoperative nausea and vomiting (PONV). We aimed to compare the effects of aprepitant on the incidence of PONV after LSG. In this double-blind, randomized controlled trial, the case group received the standard care regimen for PONV (dexamethasone 10 mg, ondansetron 4 mg, and metoclopramide 10 mg) plus prophylactic oral aprepitant 80 mg 1 h preoperatively. The control group received standard care plus a placebo. Comparative analyses using the Rhodes index were performed at 0, 6, 12, and 24 h postoperatively. A total of 400 patients (201 in the aprepitant group and 199 in the placebo group) underwent LSG. The groups were homogeneous. The aprepitant group experienced less PONV: early, 69 (34.3%) vs. 103 (51.7%), p ≤ 0.001; 6 h, 67 (33.3%) vs. 131 (65.8%), p ≤ 0.001; 12 h, 41 (20.4%) vs. 115 (57.8%), p ≤ 0.001; and 24 h, 22 (10.9%) vs. 67 (33.7%), p ≤ 0.001. Fewer patients in the aprepitant group vomited: early, 3 (1.5%) vs. 5 (2.5%), p = 0.020; 6 h, 6 (3%) vs. 18 (9%), p = 0.020; 12 h, 2 (1%) vs. 17 (8.5%), p = 0.006; and 24 h, 1 (0.5%) vs. 6 (3%), p = 0.040. Patients in the aprepitant group required less additional PONV medication: early, 61 (30.3%) vs. 86 (43.2), p = 0.008; 6 h, 7 (3.5%) vs. 34 (17%), p = 0.001; 12 h, 6 (3%) vs. 31 (15.6%), p ≤ 0.001; and 24 h, 5 (2.5%) vs. 11 (5.5%), p ≤ 0.001. Prophylactic aprepitant improved PONV between 0 h (early) and 24 h postoperatively in patients undergoing LSG.
Identifiants
pubmed: 38429485
doi: 10.1007/s11695-024-07129-0
pii: 10.1007/s11695-024-07129-0
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Camilleri M, Acosta A. Combination therapies for obesity. Metab Syndr Relat Disord. 2018;16:390–4.
doi: 10.1089/met.2018.0075
pubmed: 29993319
pmcid: 6167613
Ashoor TM, Kassim DY, Esmat IM. A randomized controlled trial for prevention of postoperative nausea and vomiting after laparoscopic sleeve gastrectomy: aprepitant/dexamethasone vs. mirtazapine/dexamethasone. Anesthesiol Res Pract. 2022;2022:3541073.
pubmed: 35535050
pmcid: 9078838
Groene P, Eisenlohr J, Zeuzem C, Dudok S, Karcz K, Hofmann-Kiefer K. Postoperative nausea and vomiting in bariatric surgery compared to non-bariatric gastric surgery. Wideochir Inne Tech Maloinwazyjne. 2019;14:90–5.
pubmed: 30766634
Moon HY, Baek CW, Choi GJ, Shin HY, Kang H, Jung YH, et al. Palonosetron and aprepitant for the prevention of postoperative nausea and vomiting in patients indicated for laparoscopic gynaecologic surgery: a double-blind randomised trial. BMC Anesthesiol. 2014;14:68. https://doi.org/10.1186/1471-2253-14-68 .
doi: 10.1186/1471-2253-14-68
pubmed: 25165427
pmcid: 4146452
Gan TJ, Belani KG, Bergese S, Chung F, Diemunsch P, Habib AS, et al. Fourth consensus guidelines for the management of postoperative nausea and vomiting. Anesth Analg. 2020;131:411–48. https://doi.org/10.1213/ANE.0000000000004833 .
doi: 10.1213/ANE.0000000000004833
pubmed: 32467512
Sinha AC, Singh PM, Williams NW, Ochroch EA, Goudra BG. Aprepitant’s prophylactic efficacy in decreasing postoperative nausea and vomiting in morbidly obese patients undergoing bariatric surgery. Obes Surg. 2014;24(2):225–31. https://doi.org/10.1007/s11695-013-1065-1 .
doi: 10.1007/s11695-013-1065-1
pubmed: 23990451
Okafor D, Kaye AD, Kaye RJ, Urman RD. The role of neurokinin-1 (substance P) antagonists in the prevention of postoperative nausea and vomiting. J Anaesthesiol Clin Pharmacol. 2017;33:441–5. https://doi.org/10.4103/0970-9185.222511 .
doi: 10.4103/0970-9185.222511
pubmed: 29416232
pmcid: 5791253
Gan TJ, Apfel CC, Kovac A, Philip BK, Singla N, Minkowitz H, et al. A randomized, double-blind comparison of the NK1 antagonist, aprepitant, versus ondansetron for the prevention of postoperative nausea and vomiting. Anesth Analg. 2007;104:1082–9. https://doi.org/10.1213/01.ane.0000263277.35140.a3
doi: 10.1213/01.ane.0000263277.35140.a3
pubmed: 17456656
Rhodes VA, McDaniel RW. The index of nausea, vomiting, and retching: a new format of the lndex of nausea and vomiting. Oncol Nurs Forum. 1999;26:889–94.
pubmed: 10382187
Habib AS, Chen YT, Taguchi A, Hu XH, Gan TJ. Postoperative nausea and vomiting following inpatient surgeries in a teaching hospital: a retrospective database analysis. Curr Med Res Opin. 2006;22(6):1093–9. https://doi.org/10.1185/030079906X104830 .
doi: 10.1185/030079906X104830
pubmed: 16846542
Schumann R, Ziemann-Gimmel P, Sultana A, Eldawlatly AA, Kothari SN, Shah S, et al. Postoperative nausea and vomiting in bariatric surgery: a position statement endorsed by the ASMBS and the ISPCOP. Surg Obes Relat Dis. 2021;17:1829–33. https://doi.org/10.1016/j.soard.2021.08.005 .
doi: 10.1016/j.soard.2021.08.005
pubmed: 34462224
Qiu T, Men P, Xu X, Zhai S, Cui X. Antiemetic regimen with aprepitant in the prevention of chemotherapy-induced nausea and vomiting: an updated systematic review and meta-analysis. Med (Baltim). 2020;99:e21559. https://doi.org/10.1097/MD.0000000000021559 .
doi: 10.1097/MD.0000000000021559
Bataille A, Letourneulx JF, Charmeau A, Lemedioni P, Léger P, Chazot T, et al. Impact of a prophylactic combination of dexamethasone-ondansetron on postoperative nausea and vomiting in obese adult patients undergoing laparoscopic sleeve gastrectomy during closed-loop propofol-remifentanil anesthesia. Eur J Anaesthesiol. 2016;33:898–905. https://doi.org/10.1097/EJA.0000000000000427 .
doi: 10.1097/EJA.0000000000000427
pubmed: 26866433
Benevides ML, Oliveira SS, de Aguilar-Nascimento JE. The combination of haloperidol, dexamethasone, and ondansetron for prevention of postoperative nausea and vomiting in laparoscopic sleeve gastrectomy: a randomized double-blind trial. Obes Surg. 2013;23:1389–96. https://doi.org/10.1007/s11695-013-0923-1 .
doi: 10.1007/s11695-013-0923-1
pubmed: 23529851
Ho KY, Chiu JW. Multimodal antiemetic therapy and emetic risk profiling. Ann Acad Med Singap. 2005 Mar;34(2):196–205. https://pubmed.ncbi.nlm.nih.gov/15827668/
Otsuka M, Yoshioka K. Neurotransmitter functions of mammalian tachykinins. Physiol Rev. 1993;73:229–308. https://doi.org/10.1152/physrev.1993.73.2.229 .
doi: 10.1152/physrev.1993.73.2.229
pubmed: 7682720
Van Laere K, De Hoon J, Bormans G, Koole M, Derdelinckx I, De Lepeleire I, et al. Equivalent dynamic human brain NK1-receptor occupancy following single-dose i.v. fosaprepitant vs. oral aprepitant as assessed by PET imaging. Clin Pharmacol Ther. 2012;92:243–50. https://doi.org/10.1038/clpt.2012.62.
doi: 10.1038/clpt.2012.62.
pubmed: 22739139
Singh PM, Borle A, Rewari V, Makkar JK, Trikha A, Sinha AC, et al. Aprepitant for postoperative nausea and vomiting: a systematic review and meta-analysis. Postgrad Med J. 2016;92:87–98. https://doi.org/10.1136/postgradmedj-2015-133515 .
doi: 10.1136/postgradmedj-2015-133515
pubmed: 26627976
Hesketh PJ. Chemotherapy-induced nausea and vomiting. N Engl J Med. 2008 Jun 5;358(23):2482–94. https://doi.org/10.1056/NEJMra0706547 .
Roila F, Molassiotis A, Herrstedt J, et al. MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting. Ann Oncol. 2016;27(suppl 5):v119–33. https://doi.org/10.1093/annonc/mdw270 .
doi: 10.1093/annonc/mdw270
pubmed: 27664248
Therneau IW, Martin EE, Sprung J, Kellogg TA, Schroeder DR, Weingarten TN. The role of aprepitant in prevention of postoperative nausea and vomiting after bariatric surgery. Obes Surg. 2018;28(1):37–43. https://doi.org/10.1007/s11695-017-2797-0 .
doi: 10.1007/s11695-017-2797-0
pubmed: 28674839
Diemunsch P, Apfel C, Gan TJ, Candiotti K, Philip BK, Chelly J, et al. Preventing postoperative nausea and vomiting: post hoc analysis of pooled data from two randomized active-controlled trials of aprepitant. Curr Med Res Opin. 2007;23:2559–65. https://doi.org/10.1185/030079907X233115 .
doi: 10.1185/030079907X233115
pubmed: 17845742
Apfel CC, Läärä E, Koivuranta M, Greim CA, Roewer N. A simplified risk score for predicting postoperative nausea and vomiting: conclusions from cross-validations between two centers. Anesthesiology. 1999 Sep;91(3):693–700. https://pubmed.ncbi.nlm.nih.gov/17236637/ .
Jung WS, Kim YB, Park HY, Choi WJ, Yang HS. Oral administration of aprepitant to prevent postoperative nausea in highly susceptible patients after gynecological laparoscopy. J Anesth. 2013;27:396–401. https://doi.org/10.1007/s00540-012-1529-9 .
doi: 10.1007/s00540-012-1529-9
pubmed: 23224788
Suh S, Helm M, Kindel TL, Goldblatt MI, Gould JC, Higgins RM. The impact of nausea on post-operative outcomes in bariatric surgery patients. Surg Endosc. 2020;34:3085–91. https://doi.org/10.1007/s00464-019-07058-5 .
doi: 10.1007/s00464-019-07058-5
pubmed: 31388805
Lim CS, Ko YK, Kim YH, Park SI, Kim JK, Kim MJ, et al. Efficacy of the oral neurokinin-1 receptor antagonist aprepitant administered with ondansetron for the prevention of postoperative nausea and vomiting. Korean J Anesthesiol. 2013;64:212–7. https://doi.org/10.4097/kjae.2013.64.3.212 .
doi: 10.4097/kjae.2013.64.3.212
pubmed: 23560185
pmcid: 3611069
Liu Y, Chen X, Wang X, et al. The efficacy of aprepitant for the prevention of postoperative nausea and vomiting: a meta-analysis. Medicine (Baltimore). 2023;102(29):e34385. https://doi.org/10.1097/MD.0000000000034385 .
doi: 10.1097/MD.0000000000034385
pubmed: 37478247
Gero D, Raptis DA, Vleeschouwers W, van Veldhuisen SL, Martin AS, Xiao Y, et al. Defining global benchmarks in bariatric surgery: a retrospective multicenter analysis of minimally invasive roux-en-y gastric bypass and sleeve gastrectomy. Ann Surg. 2019;270(5):859–67. https://doi.org/10.1097/SLA.0000000000003512 .
doi: 10.1097/SLA.0000000000003512
pubmed: 31592894